Seeking Alpha

Acadia jumps as article predicts blockbuster pimavanserin sales

  • Acadia Pharmaceuticals (ACAD +9.3%) is enjoying a strong session.
  • Perhaps helping to tip sentiment is SA Contributor Brian Nichols, who says the company's antipsychotic drug pimavanserin has "the greatest sales potential since Lipitor" — good news, considering Lipitor is the best-selling drug in pharmaceutical history.
  • Nichols goes on to predict peak global sales of $20.45B, and says his "five key points ... suggest that sales could be even greater."
  • As for a target price, Nichols says three times sales for companies with assumed blockbusters (cited are Alexion and Pharmacyclics) isn't unreasonable, and just to be on the safe side, the author discounts peak sales by "a whopping 50%," then multiplies $10B times three to get a valuation of ~$30B.
  • Ultimately, Nichols says "a target price over $300 is not unrealistic." This represents upside of around 1,295% from Friday's close.
Comments (13)
  • chasingthealpha
    , contributor
    Comments (121) | Send Message
     
    Brian Nichols, pumper extraordinaire
    14 Oct 2013, 02:56 PM Reply Like
  • beaky
    , contributor
    Comments (28) | Send Message
     
    I don't have time, I need it at $300 by thursday
    14 Oct 2013, 03:13 PM Reply Like
  • kaysmooth319
    , contributor
    Comments (319) | Send Message
     
    I need 300 by todays close, I have 1000 shares, be happy little boy
    15 Oct 2013, 05:14 PM Reply Like
  • TiantongQ
    , contributor
    Comments (246) | Send Message
     
    The best market current ever.
    14 Oct 2013, 03:28 PM Reply Like
  • fafatooey
    , contributor
    Comments (365) | Send Message
     
    The Mother of all Market Currents.
    14 Oct 2013, 04:21 PM Reply Like
  • bluesfreak
    , contributor
    Comments (39) | Send Message
     
    As if...as if there are more customers for antipsychotics as there are for high cholesterol!
    14 Oct 2013, 05:41 PM Reply Like
  • whosez
    , contributor
    Comments (107) | Send Message
     
    You might be surprised.
    14 Oct 2013, 10:42 PM Reply Like
  • bluesfreak
    , contributor
    Comments (39) | Send Message
     
    As if... as if there are more customers for anti-psychotics than for high-cholestoral!
    14 Oct 2013, 05:42 PM Reply Like
  • impopo
    , contributor
    Comments (9) | Send Message
     
    Does anyone know which drug is the TOP seller for Q2 2013???
    Lipitor? nope. Viagra? nope. Crestor? nope. AIDS med? nope.. Insulin? nope!!

     

    It's Abilify. An antipsychotic. Now Pimavanserin will the be new king in that class in the near future IMHO.

     

    1.6 billion in Q2 2013.
    14 Oct 2013, 10:59 PM Reply Like
  • Crash survivor87
    , contributor
    Comments (66) | Send Message
     
    Why didn't you earn your whopping 1300%?
    It was possible for early birds.

     

    Congrats, we had so much fun.
    15 Oct 2013, 01:44 AM Reply Like
  • bluesfreak
    , contributor
    Comments (39) | Send Message
     
    Abilify has been advertised and sold as an adjunct for major depression, hence the increased sales.
    15 Oct 2013, 11:51 AM Reply Like
  • bluesfreak
    , contributor
    Comments (39) | Send Message
     
    According to Forbes magazine,
    1/28/2013, Lipitor is #1, Abilify is #7.
    15 Oct 2013, 12:02 PM Reply Like
  • chasingthealpha
    , contributor
    Comments (121) | Send Message
     
    Keep dreaming....
    15 Oct 2013, 01:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|